drugset / Trial / NCT04736966
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase I clinical trial to determine the safety and tolerability of an anti-IL23 antibody for the treatment of patients with alcoholic liver disease
Timeline
- Start
- 2021-03-03
- Primary completion
- 2024-03-31
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 30 mg | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | 70 mg | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | 100 mg | Subcutaneous |